Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma Sep 29, 2016
Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant Sep 12, 2016
Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference Sep 6, 2016
UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Aug 12, 2016
Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Aug 11, 2016
Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance Aug 8, 2016
Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study Aug 3, 2016
Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations Jul 20, 2016
